AN2 Therapeutics ANTX 深 滬
等待開盤 07-23 09:30:00 美东时间
4.89
-0.110
-2.20%
華盛通- 最 高5.12
- 今 開4.98
- 成交量 14.21万股
- 最 低 4.75
- 昨 收 5.00
- 總市值 1.76亿
- 52周最高 6.9099
- 市盈率 靜 --
- 換手率 0.39%
- 52周最低 1.00
- 委 比 -69.06%
- 總股本 3601.62万
- 歷史最高 23.58
- 量 比 0.94
- 振 幅 7.40%
- 歷史最低 0.87
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9
Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy rating and announces Price Target of $9.
07-20 20:03
AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humansPhase 1 First-In-Human (FIH) study showed
06-04 19:09
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform and announces $9 price target.
05-15 04:35
AN2 Therapeutics Initiates Phase 2 Trial Of leucyl-tRNA Synthetase (LeuRS) Mycobacterium Abscessus, With Topline Data Planned For Late 2027
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2
03-31 19:07
AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 16 percent decrease over losses of $(0.25) per share from
03-18 04:07
